Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AN2 Therapeutics, Inc. - Common Stock
(NQ:
ANTX
)
1.370
-0.020 (-1.44%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AN2 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 06, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 18, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
September 13, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff
September 06, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
August 23, 2023
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
August 17, 2023
Via
Benzinga
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 15, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Jefferies Healthcare Conference
May 25, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 16, 2023
Via
Benzinga
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
May 01, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 29, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
January 31, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Dip
January 27, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Lennar To Rally Around 14%? Plus Keybanc Predicts $5,120 For This Stock
November 14, 2022
Keybanc boosted the price target on Lennar Corporation (NYSE: LEN) from $89 to $100. Lennar shares fell 0.4% to close at $88.03 on Friday.
Via
Benzinga
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 09, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 19, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Uber, Lyft, AZZ And Other Big Losers From Tuesday
October 12, 2022
U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
October 12, 2022
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday.
Via
Benzinga
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 06, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 29, 2022
NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
September 28, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.